Investor Presentaiton
US Business - Significant Ramp-up in Sales
SUN
PHARMA
10 year CAGR 47%
35
23
14
5
15
3
4
11
FY05
FY06
FY07
FY05 - FY14 numbers exclude Ranbaxy financials
*
FY15 numbers include the impact of Ranbaxy merger
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
Sales in Rs billion!
98
137
FY98
Key Milestones in US
FY98-FY10
•
FY08 onwards
FY10
•
•
Entry in US through Caraco
acquisition
Ramp-up in US business
Launched many complex generics
& few FTFs
• Acquired Taro Pharma – Entry into
dermatology market
=2
62
•
FY13
Acquired DUSA - Entry in
FY13
•
.
FY14
FY15
•
branded specialty market
Acquired URL's generic business
Acquired Pharmalucence -access
to sterile injectable capacity
Acquired InSite Vision -
Strengthen ophthalmic portfolio
FY13
FY14
FY15*
18View entire presentation